Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.
Sponsor: Immuneering Corporation
Summary
Atebimetinib Plus Cemiplimab, With or Without Chemotherapy, in First-Line RAS-Mutated Non-Small Cell Lung Cancer
Official title: A Phase 2, Open-Label, Multicenter, Dose Optimization and Anti-Tumor Activity Study of Atebimetinib, a Novel Oral Dual MEK1/2 Inhibitor in Combinations With Cemiplimab and Chemotherapy in First Line, RAS-mutated, Locally Advanced or Metastatic NSCLC Participants
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-12
Completion Date
2029-07
Last Updated
2026-11-19
Healthy Volunteers
No
Conditions
Interventions
Atebimetinib
Oral dual MEK1/2 inhibitor, immediate-release tablets, given once daily continuously at 160, 240 or 320 mg
Cemiplimab
Anti-PD-1 monoclonal antibody, 350 mg IV every 3 weeks
Carboplatin
AUC 5 or 6 mg/mL/min IV (Calvert formula) on Day 1 of Cycles 1-4
Pemetrexed (500 mg/m²)
500 mg/m² IV on Day 1 of Cycles 1-4
Locations (1)
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States